Results 241 to 250 of about 104,207 (331)

Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52‐week, multicentre, randomized, placebo‐controlled, phase III clinical trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the efficacy and safety of adding lobeglitazone to a triple therapy regimen in Korean patients with type 2 diabetes whose blood glucose levels were inadequately controlled despite dual therapy with metformin and sitagliptin.
Eun‐Gyoung Hong   +18 more
wiley   +1 more source

N‐lactoyl amino acids are potential biomarkers for insulin resistance and diabetic complications

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims N‐lactoyl amino acids (Lac‐AA) are emerging as crucial players in metabolic research, with potential implications for disease mechanisms and therapeutic interventions. This study exploress the role of Lac‐AA in insulin resistance, type 2 diabetes (T2D), and its complications.
Khaled Naja   +9 more
wiley   +1 more source

The gut microbiome associated with LGI1‐antibody encephalitis

open access: yesEpilepsia, EarlyView.
Abstract Objective Autoimmune encephalitis is a cause of brain inflammation characterized by auto‐antibodies, which target cell surface neuronal proteins and lead to neuronal dysfunction. The most common form is associated with auto‐antibodies to leucine‐rich glioma‐inactivated 1 (LGI1) protein, the presentation of which includes frequent focal ...
Edmund Gilbert   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy